Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChua, Kyra Y L-
dc.contributor.authorVogrin, Sara-
dc.contributor.authorBury, Susan-
dc.contributor.authorDouglas, Abby-
dc.contributor.authorHolmes, Natasha E-
dc.contributor.authorTan, Nixon-
dc.contributor.authorBrusco, Natasha K-
dc.contributor.authorHall, Rebecca-
dc.contributor.authorLambros, Belinda-
dc.contributor.authorLean, Jacinta-
dc.contributor.authorStevenson, Wendy-
dc.contributor.authorDevchand, Misha-
dc.contributor.authorGarrett, Kent-
dc.contributor.authorThursky, Karin-
dc.contributor.authorGrayson, M Lindsay-
dc.contributor.authorSlavin, Monica A-
dc.contributor.authorPhillips, Elizabeth J-
dc.contributor.authorTrubiano, Jason A-
dc.identifier.citationClinical Infectious Diseases 2020; online first: 5 Augusten
dc.description.abstractPenicillin allergies are associated with inferior patient and antimicrobial stewardship outcomes. We implemented a whole-of-hospital program to assess the efficacy of inpatient delabeling for low-risk penicillin allergies in hospitalized inpatients. Patients ≥ 18 years of age with a low-risk penicillin allergy were offered a single-dose oral penicillin challenge or direct label removal based on history (direct delabeling). The primary endpoint was the proportion of patients delabeled. Key secondary endpoints were antibiotic utilization pre- (index admission) and post-delabeling (index admission and 90 days). Between 21 January 2019 and 31 August 2019, we assessed 1791 patients reporting 2315 antibiotic allergies, 1225 with a penicillin allergy. Three hundred fifty-five patients were delabeled: 161 by direct delabeling and 194 via oral penicillin challenge. Ninety-seven percent (194/200) of patients were negative upon oral penicillin challenge. In the delabeled patients, we observed an increase in narrow-spectrum penicillin usage (adjusted odds ratio [OR], 10.51 [95% confidence interval {CI}, 5.39-20.48]), improved appropriate antibiotic prescribing (adjusted OR, 2.13 [95% CI, 1.45-3.13]), and a reduction in restricted antibiotic usage (adjusted OR, 0.38 [95% CI, .27-.54]). In the propensity score analysis, there was an increase in narrow-spectrum penicillins (OR, 10.89 [95% CI, 5.09-23.31]) and β-lactam/β-lactamase inhibitors (OR, 6.68 [95% CI, 3.94-11.35]) and a reduction in restricted antibiotic use (OR, 0.52 [95% CI, .36-.74]) and inappropriate prescriptions (relative risk ratio, 0.43 [95% CI, .26-.72]) in the delabeled group compared with the group who retained their allergy label. This health services program using a combination of direct delabeling and oral penicillin challenge resulted in significant impacts on the use of preferred antibiotics and appropriate prescribing.en
dc.subjectantibiotic allergyen
dc.subjectantimicrobial stewardshipen
dc.subjectdirect provocationen
dc.subjectoral challengeen
dc.subjectpenicillin allergyen
dc.titleThe Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Infectious Diseasesen
dc.identifier.affiliationDepartment of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Australiaen
dc.identifier.affiliationInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USAen
dc.identifier.affiliationDepartment of Medicine, Austin Health, University of Melbourne, Heidelberg, Australiaen
dc.identifier.affiliationDepartment of Oncology, Sir Peter MacCallum Cancer Centre, University of Melbourne, Parkville, Australiaen
dc.identifier.affiliationNational Centre for Antimicrobial Stewardship, Royal Melbourne Hospital, Melbourne, Australiaen
dc.identifier.affiliationInfectious Diseasesen
dc.identifier.affiliationRehabilitation, Ageing and Independent Living Research Centre, Monash University, Frankston, Australiaen
dc.identifier.affiliationAlpha Crucis Group, Health Economics, Langwarrin, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases and the National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Australiaen
dc.identifier.affiliationCentre for Antibiotic Allergy and Researchen
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 21, 2021

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.